[HTML][HTML] Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR …
K Nishie, T Kawaguchi, A Tamiya, T Mimori… - Journal of Thoracic …, 2012 - Elsevier
Introduction It is not determined whether the continuous use of epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKI) is reasonable for patients with activating …
receptor (EGFR) tyrosine kinase inhibitors (TKI) is reasonable for patients with activating …
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for …
A Inoue, K Yoshida, S Morita, F Imamura… - Japanese journal of …, 2016 - academic.oup.com
Abstract Background The Japan Guidelines of Lung Cancer Therapy recommend epidermal
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …
growth factor receptor-tyrosine kinase inhibitors as a first-line therapy for advanced/recurrent …
[HTML][HTML] Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs
JJ Lin, S Cardarella, CA Lydon, SE Dahlberg… - Journal of Thoracic …, 2016 - Elsevier
Introduction Activating mutations in the epidermal growth factor receptor gene (EGFR)
predict for prolonged progression-free survival in patients with advanced non–small cell …
predict for prolonged progression-free survival in patients with advanced non–small cell …
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer
M Takeda, I Okamoto, K Nakagawa - Lung Cancer, 2015 - Elsevier
Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …
[HTML][HTML] Tyrosine kinase inhibitors for the treatment of EGFR mutation-positive non–small-cell lung cancer: a clash of the generations
R Shah, JF Lester - Clinical lung cancer, 2020 - Elsevier
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has …
Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs
Y Liu, L Sun, ZC Xiong, X Sun, SL Zhang… - OncoTargets and …, 2017 - Taylor & Francis
Purpose The purpose of this meta-analysis was to explore the influences of pretreatment de
novo and posttreatment-acquired epidermal growth factor receptor (EGFR) T790M mutations …
novo and posttreatment-acquired epidermal growth factor receptor (EGFR) T790M mutations …
Targeting the epidermal growth factor receptor in EGFR-mutated lung cancer: current and emerging therapies
K Khaddour, S Jonna, A Deneka, JD Patel… - Cancers, 2021 - mdpi.com
Simple Summary Epidermal growth factor receptor (EGFR) mutations occur in a significant
number of lung cancer patients. Treatment outcomes in this subset of patients has greatly …
number of lung cancer patients. Treatment outcomes in this subset of patients has greatly …
[HTML][HTML] Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma
Z Lohinai, MA Hoda, K Fabian, G Ostoros… - Journal of thoracic …, 2015 - Elsevier
Introduction Although classic sensitizing mutations of epidermal growth factor receptor
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …
The presence of concomitant mutations affects the activity of EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer (NSCLC) patients
AM Rachiglio, F Fenizia, MC Piccirillo, D Galetta… - Cancers, 2019 - mdpi.com
Recent findings suggest that a fraction of EGFR-mutant non-small-cell lung cancers
(NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR …
(NSCLC) carry additional driver mutations that could potentially affect the activity of EGFR …
Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
FC Kuan, LT Kuo, MC Chen, CT Yang, CS Shi… - British journal of …, 2015 - nature.com
Background: Accumulating data shows that exon 19 deletions and L858R, both activating
epidermal growth factor receptor mutations in non-small-cell lung cancers (NSCLCs), are …
epidermal growth factor receptor mutations in non-small-cell lung cancers (NSCLCs), are …